Artio Medical is a Prairie Village, Kan.-based medical device company developing products for the peripheral vascular, neurovascular, and cardiology markets. Its core products include the recently cleared Solus Gold™ Embolization Device and the Solus Flex™ Embolization Device for peripheral vessel occlusion. The company is developing ten products for the peripheral vascular market, including the Amplifi™ Vein Dilation System to prepare hemodialysis patients for arteriovenous fistula creation. It is also developing four neurovascular products, including the Endura™ Embolization System comprising a detachable balloon and coils for treatment of saccular brain aneurysms. Artio plans to use new financing to commercialize Solus Gold in the U.S. and to advance its broader product portfolio. The company will also expand its engineering and manufacturing capabilities; the new financing brought total capital raised to date to $74m. Artio Medical is a Prairie Village, Kan.-based medical device company led by President and CEO F. Nicholas Franano, MD. It develops devices for the peripheral vascular, neurovascular, and structural heart markets. Its lead products include the Amplifi Vein Dilation System, intended to prepare hemodialysis patients for vascular access site creation, and the Solus Gold Embolization Device, a low-profile flexible catheter assembly with a non-porous, gold balloon-like implant designed for precise placement and immediate vessel occlusion. The Amplifi system has shown promising results in initial clinical testing. The company closed an additional $12M tranche of Series A financing, bringing the round total to $46M. It intends to use the funds to complete the first-in-human clinical study of Amplifi and to prepare for commercialization of Solus Gold. Artio Medical is a Fairway, Kan.-based medical device company focused on developing innovative endovascular products for the peripheral vascular, neurovascular, and structural heart markets. Its core product highlighted in the article is the Solus Gold™ Embolization Device, designed to provide precision placement, immediate occlusion, and rapid sealing of arteries, veins, saccular aneurysms, and other blood-containing structures. The company plans to use newly raised funds to obtain 510(k) marketing clearance from the U.S. Food and Drug Administration to market Solus Gold in the U.S. Artio closed an additional $8.8M in Series A financing, bringing total capital raised to date to more than $20M. The raise is intended to support regulatory clearance and U.S. commercialization efforts. The company is led by President and CEO F. Nicholas Franano, MD. Metactive Medical is developing novel medical devices and catheter delivery systems to treat neurovascular, peripheral vascular and structural heart diseases. Its first products enable precise and immediate occlusion and rapid sealing of arteries, veins, saccular aneurysms, left atrial appendages, and para-valvular leaks using detachable implants and highly flexible catheter delivery systems, including the over-the-wire Blockstent Microcatheter. The company closed an additional $1.2M in Series A financing from Mid-America Angels and Serra Ventures, bringing total funding to more than $10M to date. It was also awarded a $1.5M Phase 2 SBIR grant from the National Heart, Lung, and Blood Institute (NIH) to commercialize the Blockstent Microcatheter for occlusion of peripheral arteries and veins. The new capital and grant will be used to continue development of its platform of embolic products. Metactive is led by President and CEO F. Nicholas Franano and is based in Fairway, Kansas. Metactive Medical develops novel endovascular embolization devices delivered via an over-the-wire microcatheter platform to enable precise, immediate occlusion and rapid sealing of cerebral aneurysms and peripheral vessel segments. The company reports nonclinical data showing immediate, complete and lasting occlusion of large saccular aneurysms with rapid endothelialization of the aneurysm neck, and robust peripheral occlusion device performance. Proceeds from the recent financing will be used to continue development of devices for occlusion of saccular aneurysms and peripheral arteries and veins. Metactive’s first products are intended to be faster and easier for physicians to use and less expensive for payers relative to existing options. The article notes more than 150,000 peripheral vascular embolization procedures and more than 150,000 cerebral aneurysm embolization procedures are performed worldwide each year, indicating substantial market need. F. Nicholas Franano, MD, serves as President and CEO; the company also appointed David Ferrera to its board to support development and commercialization efforts.

Total raised

$52M

Funding rounds

5

Latest round

Series A

Latest activity

Jun 2022